Appointment of Executive Chairman

28 July 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the appointment of Helge Weiner-Trapness as Executive Chairman. Helge succeeds Peter Jensen OBE, who is stepping down from the role of Non-Executive Chairman following more than 15 years at the Group.

Helge Weiner-Trapness, who has been Chief Strategy Officer and an Executive Director of the Group since January 2026, brings more than 30 years of experience across leading global investment banks in the US and Asia, most recently as Vice Chairman, Global Banking at HSBC Holdings plc (LSE: HSBA; HKG: 0005). Helge also served on the Board of International Finance Facility for Immunisation (IFFIm), the innovative funding arm of the Vaccine Alliance (Gavi).

In his new role Helge will provide additional corporate and strategic leadership alongside Manuel Llobet, Chief Executive Officer, particularly as the Group continues to explore a potential dual primary listing on The Stock Exchange of Hong Kong Limited, alongside its existing listing on AIM.

Peter who has served on the Board since 2010 and as Chairman since 2011, has overseen a period of considerable transformation for the Group, with notable commercial and clinical progress, through a shifting regulatory landscape for allergy immunotherapies. He will continue to serve on the Board as a Non-Executive Director to allow a smooth transition and will not stand for re-election at the next Annual General Meeting. The Board extends its gratitude and appreciation for his contribution and leadership.

Helge Weiner-Trapness, newly appointed Executive Chairman of Allergy Therapeutics, said: "On behalf of the Board, I would like to thank Peter for his outstanding contributions and leadership over so many years. The strength and resilience of the Company today are testament to his commitment and significant efforts. Allergy Therapeutics has established a leading position in its core markets, with a significant portfolio and an innovative pipeline that present a strong platform for future growth. I look forward to working closely with Manuel, the Board and the management team as we pursue our growth ambitions and advance our international strategy, including through the potential dual listing in Hong Kong, which could provide access to key new markets, support expansion into Asia and create a platform to further develop our R&D capabilities."

Peter Jensen OBE, outgoing Chairman of Allergy Therapeutics, said: "It has been an immense privilege to serve as Chairman of Allergy Therapeutics Plc. Together with my colleagues on the Board and the whole Company team, we have built Allergy Therapeutics into a leading international commercial biotechnology business, and I am proud of what we have achieved together. The recent launch of Grassmuno® in Germany and the Group's wider portfolio have positioned Allergy Therapeutics for success in EU, non-EU and US markets. I am confident that, with Helge's executive leadership of the Board and Manuel's continued stewardship of the Company as CEO, Allergy Therapeutics is well placed to deliver on its next phase of growth. I look forward to supporting the Board as a Non-Executive Director in the transition period and wish everybody within the Company great success in the coming years."